


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+10.45%
-0.76%
-0.38%
+1.44%
-0.21%
GNFT
GENFIT S.A. American
$5.43
Strengths

Earnings are forecast to grow
GNFT Price Performance
$4.98 (+9.04%)
$4.3 (+26.28%)
$4.14 (+31.16%)
$3.74 (+45.19%)
GNFT has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Low volume

GNFT overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
GNFT Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
GNFT Street Sentiment is extremely bullish and have positive views on the near-term outlook
What is GNFT current stock price?
What are GNFT stock strengths?
What is GNFT Risk Level?
What is GNFT market cap and volume?
What is GNFT current Stock IQ?
Should I buy GNFT stock right now?
Is GNFT a Strong Buy right now?
What does a 'Strong Buy' rating mean for GNFT?
What does a 'Strong Sell' rating mean for GNFT?
What factors influence GNFT's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+10.45%
-0.76%
-0.38%
+1.44%
-0.21%
GNFT
GENFIT S.A. American
Current Price
$5.43
GNFT Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

GNFT Price Performance
$4.98 (+9.04%)
$4.3 (+26.28%)
$4.14 (+31.16%)
$3.74 (+45.19%)
GNFT Analysts Opinion
GNFT Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
GNFT Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
GNFT Street Sentiment is extremely bullish and have positive views on the near-term outlook
GNFT has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Low volume

GNFT Latest Analysis
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial. Lille (France) Cambridge (Massachusetts United States) Zurich (Switzerland) January 13 2026 - GENFIT (Euronext: GNFT) a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.
Tue Jan 13, 2026
GENFIT Announces 2026 Financial Calendar . Lille (France) Cambridge (Massachusetts United States) Zurich (Switzerland) January 7 2026 - GENFIT (Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases today announced its provisional financial calendar for 2026.
Wed Jan 7, 2026
GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N . Lille (France) Cambridge (Massachusetts United States) Zurich (Switzerland) January 6 2026 - GENFIT (Euronext: GNFT) a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases today announced that G1090N – a small molecule and the Companys lead investigational drug candidate for Acute-On-Chronic Liver Failure (ACLF) – demonstrate
Tue Jan 6, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
GNFT Stock trends
GNFT Stock performance
GNFT Stock analysis
GNFT investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.